UK’s NICE Namuscla Decision A ‘Red Flag’ For Repurposed Medicines
Executive Summary
Lupin and patient groups have slammed NICE’s “unprecedented” preliminary decision not to mandate funding for the repurposed rare disease treatment Namuscla for patients on England’s National Health Service who are already taking the drug. The move could set a precedent and is concerning for patients and R&D investments, says the company.
You may also be interested in...
English Funding Finally Secured For Three Previously Rejected Drugs
Lupin’s repurposed drug Namuscla, Sanofi’s Dupixent and Alnylam’s Givlaari are now deemed to be a cost-effective use of National Health Service resources.
UK Set To Launch Drug Repurposing Project
Licensing new uses of existing medicines has several benefits over off-label use, such as offering assurances that the indication is evidence based and subject to an ongoing safety monitoring program, according to a new report.
Zynteglo Funding Rejection Sets "Dangerous Precedent" For Gene Therapies In UK
bluebird is "shocked and disappointed" at the draft negative reimbursement decision on Zynteglo in UK but measures outlined in the NICE methods review could change fortunes of gene and cell therapies if taken forward.